Sarcoidosis treatment — when to start steroids and what are the indications for second-line agents?

1 Answer

Per ATS/ERS/WASOG 2023 Sarcoidosis Management Guidelines: **For this patient (Stage II, asymptomatic, FVC 75%, DLCO 62%):** The short answer is: OBSERVE, do not start steroids yet. **Indications to START Systemic Corticosteroids in Pulmonary Sarcoidosis:** 1. Progressive pulmonary involvement (FVC declining >10% per year) 2. Symptomatic disease (dyspnea affecting quality of life) 3. Radiographic worsening despite observation 4. Extra-pulmonary organ involvement (cardiac — Class I indication, neurosarcoidosis, hypercalcemia, uveitis, significant skin disease) 5. Stage III-IV disease **This patient: Stage II + mild fatigue only + FVC 75% stable** = Observe with 3-6 monthly PFTs and CXR. Stage II sarcoidosis has 60-70% spontaneous remission rate. **If treatment needed — Steroid dosing:** - Prednisolone 20-40 mg/day for 3-6 months, then taper to 10mg/day for 12-24 months total. - Taper slowly — relapse is common if stopped abruptly. **Second-line agents (steroid-sparing) — when to add:** 1. **Methotrexate (MTX) 10-15mg/week:** Most commonly used. Add when steroid dose cannot be tapered below 10mg/day without relapse, or for chronic/refractory sarcoidosis. Reduce to 7.5mg if creatinine elevated. Requires LFT monitoring. 2. **Hydroxychloroquine (200-400mg/day):** Preferred for cutaneous, hypercalcemic, and fatigue-predominant sarcoidosis. 3. **Azathioprine:** Alternative steroid-sparer for refractory pulmonary sarcoidosis. 4. **Infliximab (anti-TNF):** Reserved for severe refractory cases unresponsive to above agents. **Practical plan for this patient:** Observe 6 months. Repeat PFTs, DLCO, CXR. If FVC drops >10% or symptoms worsen, start prednisolone 20mg/day. Add MTX if steroid requirements remain high.